Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance
is a system level network phenomenon covering the entire cell. Small-scale interactomes
and signalling network models of drug resistance guide directed drug development.
Recently, proteome-wide human interactome and signalling network data have become
available, which have been extended by drug?target interactions, drug resistance-inducing
mutations, as well as by several cancer and drug resistance-related multi-omics datasets.
System level signalling network models have become available examining therapy resistance,
performing in silico clinical trials, and conducting large, in silico drug combination
screens. Drug resistance network data and models have become interoperable and reliable.
These advances paved the road for building proteome-wide drug resistance models.
